Publicación:
Erectile function in men with type 2 diabetes treated with dulaglutide: An exploratory analysis of the REWIND placebo-controlled randomised trial

Página de artículo simple
dc.contributor.authorBajaj, Harpreet S.
dc.contributor.authorGerstein, Hertzel C.
dc.contributor.authorRao-Melacini, Purnima
dc.contributor.authorBasile, Jan
dc.contributor.authorColhoun, Helen
dc.contributor.authorConget, Ignacio
dc.contributor.authorCushman, William C.
dc.contributor.authorDagenais, Gilles R.
dc.contributor.authorFranek, Edward
dc.contributor.authorHanefeld, Markolf
dc.contributor.authorKeltai, Matyas
dc.contributor.authorLakshmanan, Mark
dc.contributor.authorLanas, Fernando
dc.contributor.authorLeiter, Lawrence A.
dc.contributor.authorLopez-Jaramillo, Patricio
dc.contributor.authorPirags, Valdis
dc.contributor.authorPogosova, Nana
dc.contributor.authorProbstfield, Jeffrey
dc.contributor.authorRaubenheimer, Peter
dc.contributor.authorRyden, Lars
dc.contributor.authorShaw, Jonathan E.
dc.contributor.authorSheu, Wayne H-H.
dc.contributor.authorXavier, Denis
dc.contributor.researchgroupMasiraspa
dc.date.accessioned2022-02-23T23:03:55Z
dc.date.available2022-02-23T23:03:55Z
dc.date.issued2021-08-01
dc.descriptionDigitalspa
dc.description.abstractBackground Diabetes is a major risk factor for erectile dysfunction, however, the effect of GLP-1 receptor agonists on erectile dysfunction is unknown. We aimed to assess the incidence, prevalence, and progression of erectile dysfunction in men treated with dulaglutide compared with placebo, and to determine whether dulaglutide's effect on erectile dysfunction was consistent with its effect on other diabetes-related outcomes. Methods The Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial was a double-blind, placebo-controlled randomised trial of the effect of dulaglutide on cardiovascular outcomes. REWIND was done at 371 sites in 24 countries. Men and women aged older than 50 years with type 2 diabetes, who had either a previous cardiovascular event or cardiovascular risk factors, were randomly assigned (1:1) to receive either dulaglutide or placebo. Participating men were offered the opportunity to complete the standardised International Index of Erectile Function (IIEF) questionnaire at baseline, 2 years, 5 years, and study end. We did an exploratory analysis, in which we included participants who completed a baseline and at least 1 follow-up IIEF questionnaire. The primary outcome for these analyses was the first occurrence of moderate or severe erectile dysfunction following randomisation, assessed by the erectile function subscores on IIEF. This analysis was part of the REWIND trial, which is registered with ClinicalTrials.gov, NCT01394952. Findings Between Aug 18, 2011, and Aug 14, 2013, 3725 (70·1%) of 5312 male participants with a mean age of 65·5 years (SD 6·4 years) were analysed, of whom 1487 (39·9%) had a history of cardiovascular disease, and 2104 (56·5%) had moderate or severe erectile dysfunction at baseline. The incidence of erectile dysfunction following randomisation was 21·3 per 100 person-years in the dulaglutide group and 22·0 per 100 person-years in the placebo group (HR 0·92, 95% CI 0·85–0·99, p=0·021). Men in the dulaglutide group also had a lesser fall in erectile function subscore compared with the placebo group, with a least square mean difference of 0·61 (95% CI 0·18–1·05, p=0·006). Interpretation Long-term use of dulaglutide might reduce the incidence of moderate or severe erectile dysfunction in men with type 2 diabetes.spa
dc.description.researchareaCiencias Médicas y de la Saludspa
dc.format.extent7 pspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1016/S2213-8587(21)00115-7
dc.identifier.urihttps://repositorio.udes.edu.co/handle/001/6141
dc.language.isoengspa
dc.publisherThe Lancetspa
dc.publisher.placeReini Unidospa
dc.relation.citationendpage490spa
dc.relation.citationissue8spa
dc.relation.citationstartpage484spa
dc.relation.citationvolume9spa
dc.relation.indexedScopusspa
dc.relation.ispartofjournalThe Lancet Diabetes and Endocrinologyspa
dc.rights© 2021 The Authors, Elsevier Ltd. All rights reserved.spa
dc.rights.accessrightsinfo:eu-repo/semantics/closedAccessspa
dc.rights.creativecommonsAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/spa
dc.sourcehttps://www.thelancet.com/journals/landia/article/PIIS2213-8587(21)00115-7/fulltextspa
dc.titleErectile function in men with type 2 diabetes treated with dulaglutide: An exploratory analysis of the REWIND placebo-controlled randomised trialspa
dc.typeArtículo de revistaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.contentTextspa
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dcterms.audienceTodas las Audienciasspa
dspace.entity.typePublication
oaire.accessrightshttp://purl.org/coar/access_right/c_14cbspa
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
Archivos
Paquete original
Mostrando 1 - 1 de 1
Imagen en miniatura
Nombre:
Erectile function in men with type 2 diabetes treated with dulaglutide. An exploratory analysis of the REWIND placebo-controlled randomised trial.pdf
Tamaño:
272.66 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Paquete de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
59 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
AGBBA. Artículos de Investigación